PTC Therapeutics | PTCT

Stock Price
57.26
Daily Change
-0.75 -1.29%
Monthly
11.49%
Yearly
81.55%
Q3 Forecast
56.78

Peers Price Chg Day Year Date
Daiichi Sankyo 3,621.00 5.00 0.14% -35.87% Sep/05
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Cytokinetics 53.01 3.26 6.55% -2.00% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Ironwood Pharmaceuticals 1.16 0.06 5.00% -74.39% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
TG Therapeutics 32.21 0.32 1.00% 46.21% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05
Xencor 8.55 0.18 2.15% -47.16% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

PTC Therapeutics traded at $57.26 this Friday September 5th, decreasing $0.75 or 1.29 percent since the previous trading session. Looking back, over the last four weeks, PTC Therapeutics lost 11.49 percent. Over the last 12 months, its price rose by 81.55 percent. Looking ahead, we forecast PTC Therapeutics to be priced at 56.78 by the end of this quarter and at 55.38 in one year, according to Trading Economics global macro models projections and analysts expectations.

PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).